Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$62.1 million.

  • Relay Therapeutics' Free Cash Flow rose 1751.69% to -$62.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.9 million, marking a year-over-year increase of 1192.51%. This contributed to the annual value of -$251.1 million for FY2024, which is 1751.3% up from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Free Cash Flow is -$62.1 million, which was up 1751.69% from -$55.3 million recorded in Q2 2025.
  • Over the past 5 years, Relay Therapeutics' Free Cash Flow peaked at $46.2 million during Q1 2021, and registered a low of -$89.3 million during Q4 2023.
  • Moreover, its 5-year median value for Free Cash Flow was -$59.4 million (2022), whereas its average is -$55.9 million.
  • As far as peak fluctuations go, Relay Therapeutics' Free Cash Flow surged by 29767.06% in 2021, and later tumbled by 21257.04% in 2022.
  • Quarter analysis of 5 years shows Relay Therapeutics' Free Cash Flow stood at -$40.6 million in 2021, then tumbled by 46.34% to -$59.4 million in 2022, then crashed by 50.36% to -$89.3 million in 2023, then surged by 35.2% to -$57.9 million in 2024, then fell by 7.34% to -$62.1 million in 2025.
  • Its last three reported values are -$62.1 million in Q3 2025, -$55.3 million for Q2 2025, and -$73.6 million during Q1 2025.